Nichols & Pratt Advisers LLP MA Decreases Stock Holdings in Phreesia, Inc. (NYSE:PHR)

Nichols & Pratt Advisers LLP MA decreased its position in shares of Phreesia, Inc. (NYSE:PHRFree Report) by 38.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 37,615 shares of the company’s stock after selling 23,585 shares during the period. Nichols & Pratt Advisers LLP MA owned approximately 0.07% of Phreesia worth $703,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in PHR. Jennison Associates LLC raised its position in Phreesia by 86.7% during the second quarter. Jennison Associates LLC now owns 2,571,842 shares of the company’s stock valued at $79,753,000 after purchasing an additional 1,194,479 shares during the period. Thrivent Financial for Lutherans purchased a new stake in shares of Phreesia in the 2nd quarter worth approximately $13,668,000. BlackRock Inc. lifted its holdings in Phreesia by 5.8% during the first quarter. BlackRock Inc. now owns 6,359,641 shares of the company’s stock worth $167,640,000 after buying an additional 349,301 shares during the period. Lazard Asset Management LLC raised its position in shares of Phreesia by 102.5% in the 1st quarter. Lazard Asset Management LLC now owns 654,294 shares of the company’s stock worth $17,247,000 after acquiring an additional 331,209 shares in the last quarter. Finally, Norges Bank purchased a new stake in shares of Phreesia during the 4th quarter worth $9,435,000. 94.37% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Phreesia

In related news, CEO Chaim Indig sold 3,586 shares of the stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $24.55, for a total value of $88,036.30. Following the completion of the sale, the chief executive officer now owns 1,280,410 shares of the company’s stock, valued at $31,434,065.50. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, General Counsel Allison C. Hoffman sold 1,316 shares of the business’s stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $24.55, for a total value of $32,307.80. Following the sale, the general counsel now directly owns 144,464 shares in the company, valued at approximately $3,546,591.20. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Chaim Indig sold 3,586 shares of the company’s stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $24.55, for a total transaction of $88,036.30. Following the completion of the transaction, the chief executive officer now owns 1,280,410 shares in the company, valued at $31,434,065.50. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 9,704 shares of company stock worth $238,190. Corporate insiders own 5.80% of the company’s stock.

Phreesia Trading Up 1.4 %

PHR stock opened at $28.30 on Monday. The firm has a market cap of $1.57 billion, a P/E ratio of -10.41 and a beta of 0.95. Phreesia, Inc. has a 52-week low of $12.05 and a 52-week high of $39.59. The company has a quick ratio of 2.02, a current ratio of 2.02 and a debt-to-equity ratio of 0.03. The company’s 50-day simple moving average is $23.22 and its 200-day simple moving average is $21.56.

Phreesia (NYSE:PHRGet Free Report) last released its quarterly earnings results on Wednesday, December 6th. The company reported ($0.58) earnings per share for the quarter, topping the consensus estimate of ($0.68) by $0.10. The firm had revenue of $91.62 million during the quarter, compared to the consensus estimate of $89.60 million. Phreesia had a negative net margin of 42.70% and a negative return on equity of 54.28%. The company’s revenue for the quarter was up 25.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.76) EPS. As a group, equities analysts forecast that Phreesia, Inc. will post -2.32 EPS for the current fiscal year.

Analyst Ratings Changes

PHR has been the subject of several recent analyst reports. KeyCorp reduced their price objective on shares of Phreesia from $40.00 to $30.00 and set an “overweight” rating for the company in a research note on Thursday, December 7th. Needham & Company LLC reissued a “buy” rating and set a $29.00 price target on shares of Phreesia in a research report on Thursday, January 18th. JMP Securities dropped their price objective on shares of Phreesia from $39.00 to $28.00 and set a “market outperform” rating on the stock in a report on Wednesday, December 6th. Raymond James reduced their target price on shares of Phreesia from $30.00 to $25.00 and set an “outperform” rating for the company in a report on Thursday, December 7th. Finally, DA Davidson raised Phreesia from a “neutral” rating to a “buy” rating and increased their price target for the stock from $30.00 to $32.00 in a research report on Wednesday, January 17th. One analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $33.69.

View Our Latest Stock Analysis on PHR

Phreesia Company Profile

(Free Report)

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. Its Phreesia Platform offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.

Read More

Institutional Ownership by Quarter for Phreesia (NYSE:PHR)

Receive News & Ratings for Phreesia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phreesia and related companies with MarketBeat.com's FREE daily email newsletter.